AMO Pharma Aligns Global Trial Plan for AMO-02 in cDM1
LONDON, United Kingdom, July 6, 2026 AMO Pharma Limited has announced a significant regulatory milestone for its investigational therapy...
hematologic malignancies
Advertisement
AbbVie Wins EU Approval for TEPKINLY in Follicular Lymphoma
NORTH CHICAGO, Illinois, July 6, 2026 AbbVie has announced that the European Commission (EC) has granted marketing authorization for...
ADC Therapeutics Advances ZYNLONTA® in LOTIS-7 Lymphoma Trial
LAUSANNE, Switzerland, June 30, 2026 ADC Therapeutics SA has announced the successful completion of patient enrollment in the LOTIS-7...
FDA Clears Dexcom Stelo OTC CGM for Children
SILVER SPRING, Maryland, June 12, 2026 The U.S. Food and Drug Administration (FDA) has cleared the Dexcom Stelo Glucose...
Menarini Reports Positive Phase 3 SENTRY Data at EHA
FLORENCE, Italy and NEW YORK, June 14, 2026 Menarini Group and its oncology-focused subsidiary Stemline Therapeutics have announced promising...
Advertisements
Stelexis BioSciences Reports Breakthrough Phase 1 Eganelisib Results in AML and MDS
WALTHAM, Massachusetts, USA, June 2, 202 Stelexis BioSciences has announced encouraging Phase 1 clinical trial results for eganelisib, its...
AvenCell Therapeutics to Present First Phase 1 Results for Switchable Allogeneic CAR-T Therapy in AML
WATERTOWN, Massachusetts, USA & DRESDEN, Germany, June 2, 2026 AvenCell Therapeutics has announced that it will present results from...
Actinium Strengthens IP Portfolio for Radiotherapy Programs
NEW YORK, May 29, 2026 Actinium Pharmaceuticals, Inc. has announced the receipt of two patent allowances from the Canadian...
Nabsys Expands OhmX Platform for AML and MDS Research
San Diego, California – May 17, 2026 Nabsys 2.0 announced the expansion of its OhmX™ electronic genome mapping (EGM)...
Orca Bio Secures FDA RMAT Status for Orca-Q Therapy
MENLO PARK, Calif., April 28, 2026 Orca Bio has announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
